Compare CPA & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CPA | BLLN |
|---|---|---|
| Founded | 1947 | 2016 |
| Country | Panama | United States |
| Employees | N/A | 713 |
| Industry | Air Freight/Delivery Services | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 5.8B |
| IPO Year | 2005 | N/A |
| Metric | CPA | BLLN |
|---|---|---|
| Price | $144.71 | $137.65 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 7 |
| Target Price | ★ $159.40 | $126.71 |
| AVG Volume (30 Days) | 270.2K | ★ 592.0K |
| Earning Date | 05-13-2026 | 05-06-2026 |
| Dividend Yield | ★ 6.09% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $15.51 | $46.29 |
| Revenue Next Year | $7.25 | $30.14 |
| P/E Ratio | $9.05 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $107.44 | $61.96 |
| 52 Week High | $160.47 | $140.38 |
| Indicator | CPA | BLLN |
|---|---|---|
| Relative Strength Index (RSI) | 53.32 | 65.23 |
| Support Level | $142.23 | $79.07 |
| Resistance Level | $147.73 | $138.70 |
| Average True Range (ATR) | 3.77 | 7.64 |
| MACD | -0.02 | 0.10 |
| Stochastic Oscillator | 69.69 | 87.85 |
Copa Holdings SA is a provider of airline passenger and cargo services through its subsidiaries. The company operates through the air transportation segment. It offers international air transportation for passengers, cargo, and mail, operating from its Panama City hub in the Republic of Panama, and domestic and international air transportation for passengers, cargo, and mail with a point-to-point route network through Copa Colombia, a Colombian air carrier. The company's geographical segments are North America, South America, Central America, and the Caribbean. It derives the maximum revenue from North America.
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.